Gencurix appoints breast 카지노 바카라 specialist Professor Ahn Sei-hyun

[by Yu, Suin] Gencurix announced on August 29 that it will strengthen its business operations through the appointment of Professor Ahn Sei-hyun, a leading breast cancer specialist, and Dr. Jung Jin-koo, founder of a genetic diagnostics startup, as new members of its board of directors.

The appointment of these medical experts to the board represents a strategic initiative aimed at advancing Gencurix's precision medicine diagnostic portfolio and reinforcing its global competitiveness. Each newly appointed director is expected to play a critical role in driving the company’s precision medicine diagnostic business by applying their specialized expertise and professional insight in their respective fields.

Professor Ahn Sei-hyun is a distinguished breast 카지노 바카라 specialist who has performed more than 26,000 breast 카지노 바카라 surgeries over the course of 33 years at Asan Medical Center in Seoul, establishing himself as a leading authority in the field with globally recognized clinical experience. Beyond his significant contributions to advancing breast 카지노 바카라 treatment in Korea, he has also played a pivotal role as an educator and academic leader, training future generations of physicians and spearheading breast 카지노 바카라 research. He is credited with establishing a multidisciplinary treatment system and has delivered numerous lectures and presentations at both domestic and international medical conferences, highlighting advancements in surgical techniques and improved survival outcomes for breast 카지노 바카라 patients.

Professor Ahn currently holds a faculty position in breast surgery at Ewha Womans University Mokdong Hospital. Having integrated the full continuum of breast 카지노 바카라 management, from treatment planning through post-treatment follow-up, within a multidisciplinary care framework, he is expected to play a central role at Gencurix in validating the clinical utility of its diagnostic platform, assessing its practical applicability, and contributing to the development of its product portfolio.

Dr. Jung Jin-koo, a former surgeon at Seoul National University Hospital, is the CEO of the biotech startup Genofix. He is widely recognized for his technological expertise in the precision 카지노 바카라 diagnostics sector, having developed 카지노 바카라 diagnostic kits utilizing the CT ULTRA NGS tracking system, a liquid biopsy-based ultra-sensitive genome analysis platform, as well as UHS (ultra-high sensitivity) mutation amplification technology.

Jung is regarded as a rare expert who combines extensive clinical experience with entrepreneurial acumen. His advanced genome analysis technologies, coupled with his proven track record in commercialization, are expected to make a direct contribution to accurately identifying unmet medical needs, shaping product development directions, broadening the company's technology portfolio, and expediting the path to commercialization.

“With the addition of experts possessing world-class clinical experience and cutting-edge technological expertise, we have established a strong foundation for the advancement and global expansion of our diagnostic technologies,” said Cho Sang-rae, CEO of Gencurix. “The contributions of these two experts are expected to serve as a cornerstone in transforming our company from a purely technology-driven diagnostic company into an organization deeply grounded in medical practice and global regulatory standards,” he added.